Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Margitta Worm, Charles Lynde et al.|British Journal of Dermatology|2020Cited by 590
Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic ArthritisIrmina Olejniczak‐Staruch, Aleksandra Lesiak|International Journal of Molecular Sciences|2021Cited by 206